TY  - JOUR

T1  - Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden

JO  - European Urology Oncology

UR  - http://eprints.whiterose.ac.uk/139917/

PY  - 2018/11/22

AU  - Srivastava T

AU  - Prabhu VS

AU  - Li H

AU  - Xu R

AU  - Zarabi N

AU  - Zhong Y

AU  - Pellisier JM

AU  - Perini RF

AU  - de Wit R

AU  - Mamtani R

ED  - 

DO  - DOI: 10.1016/j.euo.2018.09.012

Y2  - 2024/12/22

ER  -